methylthiomethyl 1-naphthylmethyl ether | 88045-64-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methylthiomethyl 1-naphthylmethyl ether
• 英文别名: 1-(methylsulfanylmethoxymethyl)naphthalene
• CAS: 88045-64-1
• 化学式: C₁₃H₁₄OS
• 分子量: 218.32
• InChiKey: KEJGDVAHRMJECI-UHFFFAOYSA-N

物化性质

• 沸点：
  335.6±25.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methylthiomethyl 1-naphthylmethyl ether 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 1-(氯甲氧基甲基)萘
  参考文献：
  名称：

  Pyrimidinones as reversible metaphase arresting agents

  摘要：

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.

  DOI：

  10.1016/0223-5234(93)90014-6
• 作为产物：
  描述：

  氯甲基甲硫醚 、 1-萘甲醇 在 sodium hydride 、 sodium iodide 作用下， 生成 methylthiomethyl 1-naphthylmethyl ether
  参考文献：
  名称：

  Pyrimidinones as reversible metaphase arresting agents

  摘要：

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.

  DOI：

  10.1016/0223-5234(93)90014-6

文献信息

• Substituted pyrimidin-2-ones and the salts thereof
  申请人：Nyegaard & Co. A/S

  公开号：US04539324A1

  公开（公告）日：1985-09-03

  Compounds of the general formula: ##STR1## wherein X represents halogen or trifluoromethyl; R.sup.1 and R.sup.2, independently represent hydrogen or lower alkyl; R.sup.3, R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkenoyl, C.sub.7-16 aralkyl or C.sub.6-10 aryl or a 5-9 membered unsaturated or aromatic heterocyclic ring; one or both of R.sup.4 and R.sup.5 may also represent aroyl groups; Z represents an oxygen atom or a sulfur atom or oxide thereof or a group NR.sup.6 (wherein R.sup.6 is as defined for R hereinafter or represents the group COR.sup.7 in which R.sup.7 represents hydrogen or optionally substituted aryl, heterocyclic, aralkyl, lower alkyl or lower alkoxy group; and R represents a C.sub.6-10 carbocyclic aromatic group or a heterocyclic group containing a 5-9 membered unsaturated or aromatic heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused ring which carbocyclic or heterocyclic group may carry one or more C.sub.1-4 alkyl or phenyl groups said groups being optionally substituted; and where acid or basic groups are present, the salts thereof are useful in combating abnormal cell proliferation. The compounds of the invention are prepared by inter alia alkylation, ring closure and oxidation.

  通式为：##STR1##其中X代表卤素或三氟甲基；R.sup.1和R.sup.2分别代表氢或较低的烷基；R.sup.3、R.sup.4和R.sup.5可以相同或不同，分别代表氢、较低的烷基、较低的烯基、较低的炔基、较低的酰基、较低的烯酰基、C.sub.7-16芳基烷基或C.sub.6-10芳基或5-9成员不饱和或芳香杂环环；R.sup.4和R.sup.5中的一个或两个还可以表示芳酰基；Z代表氧原子或硫原子或其氧化物或基团NR.sup.6（其中R.sup.6如下定义或表示基团COR.sup.7，其中R.sup.7代表氢或可选择取代的芳香基、杂环基、芳基烷基、较低的烷基或较低的烷氧基；R代表C.sub.6-10的碳环芳基或含有5-9成员不饱和或芳香杂环环的杂环基，该环含有O、N和S中选择的一个或多个杂原子，并且可以携带一个或多个C.sub.1-4烷基或苯基，所述基团可以是可选择的取代基；当存在酸性或碱性基团时，其盐在对抗异常细胞增殖方面是有用的。该发明的化合物通过烷基化、环闭合和氧化等方法制备。
• US4539324A
  申请人：——

  公开号：US4539324A

  公开（公告）日：1985-09-03
• Pyrimidinones as reversible metaphase arresting agents
  作者：T Benneche、P Strande、R Oftebro、K Undheim

  DOI：10.1016/0223-5234(93)90014-6

  日期：1993.1

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.